Latest Plexxikon Stories
PARSIPPANY, N.J. and TOKYO, Feb.
Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas.
Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma
CARLSBAD, Calif., Feb.
NEW YORK, Sept.
An early-stage clinical trial of a new cancer drug could lead to the creation of effective melanoma drugs, researchers at a meeting in Orlando, Fla.,said. The Wall Street Journal said Wednesday the study presented at the American Society of Clinical Oncology's annual meeting showed a drug called PLX4032 was effectively used to shrink tumors in nine of 16 study patients.
INDIANAPOLIS, Ind. and LAWRENCE, Kan., Oct.
US-based drug discovery and development company Plexxikon has started a Phase I human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs pain as well as polycystic kidney disease.
Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has acquired from Roche the exclusive development rights for the clinical-stage compound romazarit.
- A political dynamiter.